Abstract
Synthetic compounds with a tri- and tetra-substituted imidazole scaffold are known as selective inhibitors of the p38 mitogenactivated protein (MAP) kinase responsible for proinflammatory cytokine release. The scope is to review the literature describing their design, synthesis and activity studies. To date a great plethora of crystal structures of p38 in complex with small organic ligands have been published. Cocrystallized ligand information is of particular interest to our review study, i.e. ATP itself, the reference inhibitor SB203580 with its aryl-pyridinyl-imidazoles and related imidazole and pyrimidine-based derivatives. The selective inhibitors bind to the pocket of adenosine 5'-triphoshate (ATP) replacing the latter. The hydrophobic region II, however, is not occupied by the natural binder ATP, but accommodates the pyridine substituents preserving the 4-fluorophenyl ring occupation in pocket I as a prerequisite to gain higher binding selectivity and potency than the reference compound SB203580 (4-[5-(4-fluoro-phenyl)-2-(4-methanesulfinyl-phenyl)-3himidazol- 4-yl]-pyridine). Experimental and computed work is reviewed which evidence that the 2 position of the pyrimidine ring is amenable to the introduction of a side chain and the replacement of pyridine in SB203580 by a pyrimidine ring improves both inhibitory activity and selectivity for p38 over other kinases. All ligands with a pyridyl C2 side chain occupy the hydrophobic pocket II and in some cases a double hydrogen bond is reported between methionine 109 and glycine 110 of the hinge region, following an observed backbone shift. The substituted pyridine ring binds stronger than the two other side chains on the imidazole scaffold.
Keywords: p38α MAP kinase inhibitors, 1, 2, 4, 5-tetrasubstituted imidazoles, 1, 2, 4, 5-tetrasubstituted pyrimidines, 2, 4, 5-trisubstituted or 2-benzyl thiopyrimidines, pyrimidines, 2, 4, 5-trisubstituted, 2-benzyl thiopyrimidines, Synthetic compounds, imidazole scaffold, proinflammatory, cytokine, pyrimidine-based derivatives
Current Medicinal Chemistry
Title: Pharmacophore Design of p38α MAP Kinase Inhibitors with Either 2,4,5-Trisubstituted or 1,2,4,5-Tetrasubstituted Imidazole Scaffold
Volume: 18 Issue: 10
Author(s): T. Scior, D. M. Domeyer, K. Cuanalo-Contreras and S. A. Laufer
Affiliation:
Keywords: p38α MAP kinase inhibitors, 1, 2, 4, 5-tetrasubstituted imidazoles, 1, 2, 4, 5-tetrasubstituted pyrimidines, 2, 4, 5-trisubstituted or 2-benzyl thiopyrimidines, pyrimidines, 2, 4, 5-trisubstituted, 2-benzyl thiopyrimidines, Synthetic compounds, imidazole scaffold, proinflammatory, cytokine, pyrimidine-based derivatives
Abstract: Synthetic compounds with a tri- and tetra-substituted imidazole scaffold are known as selective inhibitors of the p38 mitogenactivated protein (MAP) kinase responsible for proinflammatory cytokine release. The scope is to review the literature describing their design, synthesis and activity studies. To date a great plethora of crystal structures of p38 in complex with small organic ligands have been published. Cocrystallized ligand information is of particular interest to our review study, i.e. ATP itself, the reference inhibitor SB203580 with its aryl-pyridinyl-imidazoles and related imidazole and pyrimidine-based derivatives. The selective inhibitors bind to the pocket of adenosine 5'-triphoshate (ATP) replacing the latter. The hydrophobic region II, however, is not occupied by the natural binder ATP, but accommodates the pyridine substituents preserving the 4-fluorophenyl ring occupation in pocket I as a prerequisite to gain higher binding selectivity and potency than the reference compound SB203580 (4-[5-(4-fluoro-phenyl)-2-(4-methanesulfinyl-phenyl)-3himidazol- 4-yl]-pyridine). Experimental and computed work is reviewed which evidence that the 2 position of the pyrimidine ring is amenable to the introduction of a side chain and the replacement of pyridine in SB203580 by a pyrimidine ring improves both inhibitory activity and selectivity for p38 over other kinases. All ligands with a pyridyl C2 side chain occupy the hydrophobic pocket II and in some cases a double hydrogen bond is reported between methionine 109 and glycine 110 of the hinge region, following an observed backbone shift. The substituted pyridine ring binds stronger than the two other side chains on the imidazole scaffold.
Export Options
About this article
Cite this article as:
Scior T., M. Domeyer D., Cuanalo-Contreras K. and A. Laufer S., Pharmacophore Design of p38α MAP Kinase Inhibitors with Either 2,4,5-Trisubstituted or 1,2,4,5-Tetrasubstituted Imidazole Scaffold, Current Medicinal Chemistry 2011; 18 (10) . https://dx.doi.org/10.2174/092986711795328409
DOI https://dx.doi.org/10.2174/092986711795328409 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protein Processing and Inflammatory Signaling in Cystic Fibrosis: Challenges and Therapeutic Strategies
Current Molecular Medicine Is There a Role for PDE5 Inhibitors in the Management of Male Infertility Due to Defects in Testicular or Epididymal Function?
Current Pharmaceutical Design HSV-1 Based Amplicon Vectors as an Alternative System for the Expression of Functional HCV Proteins
Current Gene Therapy Therapeutic Implications of Tocilizumab, A Humanized Anti-Interleukin-6 Receptor Antibody, for Various Immune-Mediated Diseases: An Update Review
Current Rheumatology Reviews Optical Coherence Tomography Detection of Neurodegeneration in Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Crocetin Suppresses Uterine Ischemia/Reperfusion-induced Inflammation and Apoptosis through the Nrf-2/HO-1 Pathway
Current Molecular Medicine Characterization of Adipose-Derived Stem Cells: An Update
Current Stem Cell Research & Therapy Subject Index To Volume 5
CNS & Neurological Disorders - Drug Targets Current Prospective of Anti-IL-4, -IL-9, and -IL-13 Therapies in Allergic Disease
Recent Patents on Inflammation & Allergy Drug Discovery Editorial [Hot topic: The Inflammation Paradigm in Cardiovascular Disease (Guest Editor: Guha Krishnaswamy)]
Cardiovascular & Hematological Disorders-Drug Targets Immune Aging and Autoimmune Diseases in Children
Current Immunology Reviews (Discontinued) Translating the Potential of Stem Cells for Diabetes Mellitus: Challenges and Opportunities
Current Stem Cell Research & Therapy The Roles of Vitamin D in Increasing the Body's Immunity and Reducing Injuries due to Viral Infections: With an Emphasis on its Possible Role in SARS-CoV-2 (COVID-19)
Current Pharmaceutical Design From Test Tube to Clinical Trial; Promising Herbs with NF-κB and COX- 2 Activity
Current Immunology Reviews (Discontinued) Identification of Bioactive Natural Products by Pharmacophore-Based Virtual Screening
Current Pharmaceutical Design Metabolomics of Serum Peptides
Protein & Peptide Letters Glucagon-Like Peptide-1-Mediated Modulation of Inflammatory Pathways in the Diabetic Brain: Relevance to Alzheimer’s Disease
Current Alzheimer Research The Urokinase Receptor Interactome
Current Pharmaceutical Design Nonalcoholic Fatty Liver Disease and Cardiovascular Disease
Current Pharmaceutical Design Bacterial Outer Membrane Vesicles: An Emerging Tool in Vaccine Development, as Adjuvants, and for Therapeutic Delivery
Drug Delivery Letters